CRSP (CRISPR Therapeutics) Net Financial Result

CRSP (CRISPR Therapeutics Inc) - company brandmark

CRISPR Therapeutics AG (CRSP) net profit dynamics correlate with breakthroughs in Casgevy therapy and the development of in vivo methods. Financial success is based on licenses and grants in the field of oncology. Business efficiency is driven by a staff of top biologists who foster a culture of bold hypotheses. The value of -0.44 describes the current yield level, allowing the investor to assess the business's real ability to generate funds.

CRSP CRISPR Therapeutics Inc Company Net Income (07/04/2022 - 11/01/2026)

Comprehensive metric breakdowns and analytics for CRISPR Therapeutics (CRSP)

- stock price and consensus target price:
Price Performance Chart CRISPR|CRSP - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization CRISPR|CRSP - Total Company Value
- shareholders' equity book value data:
Net Assets per Share CRISPR Therapeutics|CRSP - Company Book Value|Market Capitalization to Net Assets crisprtx.com|CRSP - Aggregate Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio CRISPR Therapeutics AG|CRSP - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital CRISPR Therapeutics Inc|CRSP - Company Total Debt|Debt to Book Capital CRISPR|CRSP - Company Long-Term Debts|Company Short-Term Loans and Borrowings CRISPR Therapeutics|Immediate Liquidity crisprtx.com
- earnings and multiples data:
CRSP - Company Net Income
Summary company analysis:CRISPR - CRSP
Manufactured products of CRISPR Therapeutics Inc

The selection of high-quality issuers is based on an analysis of the business's ability to generate a sustainable cash flow stripped of market volatility. This indicator captures real daily returns, which for genome editing leader CRISPR Therapeutics AG (CRSP) signifies a transition from R&D investments to receiving commercial royalties, turning the company's net bottom line into an objective marker of its long-term financial stability.

Direct competitors

Tempus AI - Final Profit|QGEN (Qiagen N.V.) - Net Profit|ionispharma.com (IONS) - Net Financial Result|Company Net Income Repligen (RGEN)|Net Financial Result Avidity Biosciences Inc|Company Net Income Sema4 WGS|RARE (Ultragenyx Corp) - Profit After Tax|BEAM - Company Net Income|Final Profit SRPT (sarepta.com)|TWST (Twist Bioscience, Inc.) - Net Income|10x Genomics Inc - Final Profit|Net Income NTLA|STOK (Stoke Corp) - Profit After Payment of Taxes|Net Profit BLFS|WVE (wavelifesciences.com) - Final Profit|Net Profit MAZE (Maze Therapeutics)|Sionna Therapeutics, Inc. (SION) - Company Net Income|PRME - Company Net Income|Final Profit TSHA (Taysha Corp)|QURE: Net Profit|meiragtx.com (MGTX) - Net Profit|Company Net Income REGENXBIO|Solid Biosciences Inc - Profit After Tax|Net Profit OCGN|PACB - Company Net Income|Benitec Biopharma Inc. - Net Income|Net Profit designtx.com DSGN|RCKT: Net Income|4DMT - Profit After Payment of Taxes|LXEO: Net Profit|KRRO - Net Financial Result|EDIT (Editas Medicine, Inc.) - Net Profit|Net Income silence-therapeutics.com (SLN)|Company Net Income ProQR Therapeutics N.V. (PRQR)|Net Financial Result codexis.com|Sangamo - Net Income|Final Profit NAUT|Metagenomi, Inc. - Net Profit|DTIL - Net Profit|GBIO: Net Profit|Annual Net Income Boundless Bio Inc. BOLD|XCUR (Exicure Inc.) - Net Profit|Net Income Celsion Corporation (IMNN)|Company Net Income Phio Pharmaceuticals (PHIO)|MBIO (mustangbio.com) - Final Profit|Company Net Income TransCode Therapeutics, Inc. RNAZ|Net Financial Result Bionano Genomics Inc. (BNGO)|APDN - Company Net Income|Profit After Tax BLUE|IPA: Net Profit|Company Profit OMGA|Company Net Income Singular Genomics|Company Profit RGLS (Regulus Therapeutics, Inc.)|Net Profit SYRS|Net Profit Telesis Bio, Inc (TBIO)|Net Profit TCON (TRACON Pharmaceuticals)|UBX - Net Income